Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone By Ogkologos - June 24, 2025 832 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer June 4, 2020 Adjuvant Treatment with Nivolumab Plus Ipilimumab Combination Fails to Improve DFS... February 22, 2023 Cancer Rehabilitation Starts at Diagnosis July 6, 2021 Mom Who Lost Child Donates Breast Milk To Mom With Cancer February 27, 2019 Load more HOT NEWS Simple Hysterectomy May Expand Treatment Options for Early-Stage Cervical Cancer EMA Recommends Extension of Indications for Cemiplimab Rapid, Robust and Durable Antitumour Activity of Pralsetinib in Patients with... Embedding research integrity at the core of our science
